Skip to main content
    A

    Anika Therapeutics Inc (ANIK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $12.92
    -0.48 (-3.58%)

    Market Cap: $179.50M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Anika Therapeutics Inc (ANIK) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    Anika Therapeutics reported revenue of $112.82M for the fiscal year ended Dec 31, 2025, down 5.9% from the year before. That year, net income was -$10.88M with a net margin of -9.6%, operating cash flow was $11.19M and free cash flow was $4.36M. The quarter ended Sep 30, 2026 had revenue of $30.59M and net income of -$311.00K.

    Revenue and Margins

    The operating margin was -9.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $103.38M, a compound annual rate of 1.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$112.82M-5.9%56.6%-9.8%-9.6%
    Dec 2024$119.91M-0.7%63.4%-4.3%-47.0%
    Dec 2023$120.79M+6.1%68.3%0.7%-68.4%
    Dec 2022$113.83M-23.0%64.3%3.2%-13.1%
    Dec 2021$147.79M+13.3%56.1%1.8%2.8%
    Dec 2020$130.46M+13.8%52.9%-21.7%-18.4%
    Dec 2019$114.61M+8.6%74.9%29.9%23.7%
    Dec 2018$105.56M-6.9%70.4%20.6%17.7%
    Dec 2017$113.42M+9.7%75.9%40.3%28.1%
    Dec 2016$103.38MN/A76.8%49.0%31.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$112.82M$119.91M$120.79M$113.83M$147.79M$130.46M$114.61M$105.56M$113.42M$103.38M
    Cost of revenue$49.01M$43.91M$38.26M$40.61M$64.85M$61.43M$28.75M$31.28M$27.36M$24.03M
    Gross profit$63.81M$76.00M$82.53M$73.22M$82.94M$69.03M$85.86M$74.28M$86.06M$79.35M
    Research and development$25.77M$25.54M$21.76M$18.32M$27.33M$23.43M$16.66M$18.19M$18.79M$10.73M
    Operating income-$11.05M-$5.10M$844.00K$3.67M$2.62M-$28.32M$34.25M$21.75M$45.73M$50.61M
    Net income-$10.88M-$56.38M-$82.67M-$14.86M$4.13M-$23.98M$27.19M$18.72M$31.82M$32.55M
    EBITDA-$5.32M$3.02M$15.06M$18.16M$23.40M-$22.24M$41.42M$27.29M$50.02M$54.34M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$30.59M$32.61M$29.61M$30.61M$27.82M$28.22M$26.17M$30.60M$29.56M$30.72M$29.02M-$2.90M
    Gross profit$18.84M$21.24M$19.00M$19.18M$15.58M$14.36M$14.68M$17.13M$19.41M$20.49M$18.98M$5.77M
    Operating income-$712.00K$2.95M-$5.49M$646.00K-$3.23M-$4.18M-$4.28M-$705.00K-$81.00K-$1.81M-$2.50M$24.70M
    Net income-$311.00K$3.31M-$5.06M$292.00K-$2.33M-$3.97M-$4.87M-$21.86M-$29.92M-$88.00K-$4.51M-$63.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.05M by $55.43M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$190.27M$202.74M$270.63M$349.13M$347.54M$365.61M$330.71M$278.99M$282.62M$240.25M
    Current assets$103.36M$113.65M$163.31M$169.55M$168.53M$177.38M$234.31M$202.94M$206.33M$170.44M
    Cash and equivalents$57.48M$55.63M$68.74M$86.33M$94.39M$95.82M$157.46M$89.04M$133.26M$104.26M
    Total liabilities$46.80M$48.75M$58.37M$63.56M$60.45M$93.20M$42.33M$15.38M$19.13M$17.47M
    Short-term debt$2.05M$1.92M$1.83M$2.07M$4.32M$13.09M$0N/AN/A$48.00K
    Shareholder equity$143.47M$153.99M$212.26M$285.56M$287.08M$272.40M$288.38M$263.61M$263.49M$222.77M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$189.60M$183.47M$179.39M$190.27M$189.44M$187.68M$190.60M$202.74M$231.41M$262.65M$263.74M$270.63M
    Total liabilities$52.02M$46.19M$45.49M$46.80M$42.63M$40.01M$42.21M$48.75M$51.54M$52.32M$55.21M$58.37M
    Cash and equivalents$44.96M$38.41M$41.02M$57.48M$57.99M$53.17M$53.37M$55.63M$62.37M$62.82M$68.63M$68.74M
    Shareholder equity$137.58M$137.28M$133.90M$143.47M$146.81M$147.67M$148.40M$153.99M$179.86M$210.34M$208.54M$212.26M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 39.0% of operating cash flow. Share repurchases came to 217.4% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$11.19M$5.40M-$1.79M$4.41M$8.40M$13.06M$37.01M$34.92M$40.81M$24.45M
    Capital expenditures$6.83M$7.73M$5.43M$7.49M$5.14M$1.63M$2.83M$4.66M$8.98M$14.01M
    Free cash flow$4.36M-$2.33M-$7.21M-$3.08M$3.25M$11.44M$34.18M$30.26M$31.83M$10.43M
    Dividends paidN/AN/AN/A$253.00K$642.00K$1.26MN/AN/A$0$0
    Share repurchases$9.48M$10.91M$5.00M$0$0N/A$30.00M$30.00M$0$25.00M
    Investing cash flow-$401.00K-$8.33M-$5.43M-$7.49M-$3.12M-$71.26M$39.69M-$50.26M-$12.48M-$6.76M
    Financing cash flow-$10.55M-$12.73M-$6.32M-$4.85M-$6.78M-$3.77M-$8.14M-$28.90M$314.00K-$23.99M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$8.38M-$684.00K-$4.85M$4.64M$6.87M-$189.00K-$130.00K$1.58M$5.02M-$1.07M-$126.00K$3.64M
    Capital expenditures$1.66M$1.45M$1.43M$648.00K$1.89M$1.47M$2.82M$1.31M$1.22M$3.40M$1.81M$1.84M
    Free cash flow$6.72M-$2.13M-$6.28M$3.99M$4.98M-$1.66M-$2.95M$275.00K$3.80M-$4.47M-$1.93M$1.80M
    Last 12 quarters

    Frequently Asked Questions About ANIK

    What is Anika Therapeutics' annual revenue?

    Anika Therapeutics reported revenue of $112.82M for the fiscal year ended Dec 31, 2025.

    How fast is Anika Therapeutics' revenue growing?

    Revenue was down 5.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.3%.

    Is Anika Therapeutics profitable?

    No. Anika Therapeutics reported net income of -$10.88M for the fiscal year ended Dec 31, 2025, with a net margin of -9.6%.

    How much free cash flow does ANIK generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $11.19M minus capital expenditures of $6.83M produced free cash flow of $4.36M.

    How much debt does Anika Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.05M and cash and equivalents of $57.48M.